These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 27744704)

  • 21. Stimuli-responsive, dual-function prodrug encapsulated in hyaluronic acid micelles to overcome doxorubicin resistance.
    Qiu L; Xu J; Ahmed KS; Zhu M; Zhang Y; Long M; Chen W; Fang W; Zhang H; Chen J
    Acta Biomater; 2022 Mar; 140():686-699. PubMed ID: 34875359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism.
    Shen J; He Q; Gao Y; Shi J; Li Y
    Nanoscale; 2011 Oct; 3(10):4314-22. PubMed ID: 21892492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Co-delivery of doxorubicin and P-gp inhibitor by a reduction-sensitive liposome to overcome multidrug resistance, enhance anti-tumor efficiency and reduce toxicity.
    Tang J; Zhang L; Gao H; Liu Y; Zhang Q; Ran R; Zhang Z; He Q
    Drug Deliv; 2016 May; 23(4):1130-43. PubMed ID: 25491241
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coencapsulated doxorubicin and bromotetrandrine lipid nanoemulsions in reversing multidrug resistance in breast cancer in vitro and in vivo.
    Cao X; Luo J; Gong T; Zhang ZR; Sun X; Fu Y
    Mol Pharm; 2015 Jan; 12(1):274-86. PubMed ID: 25469833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. pH-responsive polymeric micelles based on poly(2-ethyl-2-oxazoline)-poly(D,L-lactide) for tumor-targeting and controlled delivery of doxorubicin and P-glycoprotein inhibitor.
    Zhao Y; Zhou Y; Wang D; Gao Y; Li J; Ma S; Zhao L; Zhang C; Liu Y; Li X
    Acta Biomater; 2015 Apr; 17():182-92. PubMed ID: 25612838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Barbigerone reverses multidrug resistance in breast MCF-7/ADR cells.
    Li X; Wan L; Wang F; Pei H; Zheng L; Wu W; Ye H; Wang Y; Chen L
    Phytother Res; 2018 Apr; 32(4):733-740. PubMed ID: 29368443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Folate-modified poly(2-ethyl-2-oxazoline) as hydrophilic corona in polymeric micelles for enhanced intracellular doxorubicin delivery.
    Qiu LY; Yan L; Zhang L; Jin YM; Zhao QH
    Int J Pharm; 2013 Nov; 456(2):315-24. PubMed ID: 24016742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP.
    Dong X; Mattingly CA; Tseng MT; Cho MJ; Liu Y; Adams VR; Mumper RJ
    Cancer Res; 2009 May; 69(9):3918-26. PubMed ID: 19383919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Folate and CD44 receptors dual-targeting hydrophobized hyaluronic acid paclitaxel-loaded polymeric micelles for overcoming multidrug resistance and improving tumor distribution.
    Liu Y; Sun J; Lian H; Cao W; Wang Y; He Z
    J Pharm Sci; 2014 May; 103(5):1538-47. PubMed ID: 24619562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor.
    Lee ES; Na K; Bae YH
    J Control Release; 2005 Mar; 103(2):405-18. PubMed ID: 15763623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel -polymer micelles to overcome multi-drug resistance.
    Wang F; Zhang D; Zhang Q; Chen Y; Zheng D; Hao L; Duan C; Jia L; Liu G; Liu Y
    Biomaterials; 2011 Dec; 32(35):9444-56. PubMed ID: 21903258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel oral administrated paclitaxel micelles with enhanced bioavailability and antitumor efficacy for resistant breast cancer.
    Zhang T; Luo J; Fu Y; Li H; Ding R; Gong T; Zhang Z
    Colloids Surf B Biointerfaces; 2017 Feb; 150():89-97. PubMed ID: 27898360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Folate-Targeted Redox-Responsive Polymersomes Loaded with Chemotherapeutic Drugs and Tariquidar to Overcome Drug Resistance.
    Qin Y; Zhang Z; Huang C; Fan F; Liu L; Lu L; Wang H; Liu Z; Yang J; Wang C; Yang H; Sun H; Leng X; Kong D; Zhang L; Zhu D
    J Biomed Nanotechnol; 2018 Oct; 14(10):1705-1718. PubMed ID: 30041718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
    Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
    Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanism study of PEGylated polyester and β-cyclodextrin integrated micelles on drug resistance reversal in MRP1-overexpressed HL60/ADR cells.
    Ji Q; Qiu L
    Colloids Surf B Biointerfaces; 2016 Aug; 144():203-213. PubMed ID: 27088190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin.
    Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H
    Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TPGS/Phospholipids Mixed Micelles for Delivery of Icariside II to Multidrug-Resistant Breast Cancer.
    Song J; Huang H; Xia Z; Wei Y; Yao N; Zhang L; Yan H; Jia X; Zhang Z
    Integr Cancer Ther; 2016 Sep; 15(3):390-9. PubMed ID: 26293804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paclitaxel-loaded N-octyl-O-sulfate chitosan micelles for superior cancer therapeutic efficacy and overcoming drug resistance.
    Jin X; Mo R; Ding Y; Zheng W; Zhang C
    Mol Pharm; 2014 Jan; 11(1):145-57. PubMed ID: 24261922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A safe, simple and efficient doxorubicin prodrug hybrid micelle for overcoming tumor multidrug resistance and targeting delivery.
    Bao Y; Yin M; Hu X; Zhuang X; Sun Y; Guo Y; Tan S; Zhang Z
    J Control Release; 2016 Aug; 235():182-194. PubMed ID: 27264552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Doxorubicin and lapatinib combination nanomedicine for treating resistant breast cancer.
    Wang H; Li F; Du C; Wang H; Mahato RI; Huang Y
    Mol Pharm; 2014 Aug; 11(8):2600-11. PubMed ID: 24405470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.